Description

Wegovy is used together with diet and physical activity to help people to lose weight and keep their weight under control. It is used in adults who have:
• a BMI of 30 kg/m² or greater (obesity) or
• a BMI of at least 27 kg/m² but less than 30 kg/m² (overweight) who have weight-related health problems (such as diabetes, high blood pressure, abnormal levels of fats in the blood, breathing problems during sleep called ‘obstructive sleep apnoea’ or a history of heart attack, stroke or blood vessel problems).
It is also used in adolescents from 12 years of age whose BMI is at or above the 95th percentile for their age and gender (obesity) and who weigh more than 60 kg.
BMI (body mass index) is a measure of your weight in relation to your height. A BMI at the 95th percentile means that it is greater than that of 95% of people of the same age and gender.
Wegovy contains the active substance semaglutide.
Wegovy is available as pre-filled pens containing a solution for injection. It is injected once a week under the skin in the belly, thigh or upper arm.
To reduce the risk of symptoms affecting the gut, the weekly dose is gradually increased over 16 weeks.
Patients can administer the medicine themselves.
The medicine can only be obtained with a prescription. For more information about using Wegovy, see the package leaflet or contact your healthcare provider.
The active substance in Wegovy, semaglutide, is a ‘GLP-1 receptor agonist’. It acts in the same way as GLP-1 (a natural hormone in the body) and, among other things, appears to regulate appetite by increasing a person’s feelings of fullness, while reducing their food intake, hunger and cravings.